Viewing Study NCT05488405


Ignite Creation Date: 2025-12-25 @ 3:31 AM
Ignite Modification Date: 2026-03-09 @ 4:06 AM
Study NCT ID: NCT05488405
Status: COMPLETED
Last Update Posted: 2023-09-07
First Post: 2022-08-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Mesalazine Oral Suspension in Active Eosinophilic Esophagitis
Sponsor: Dr. Falk Pharma GmbH
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Eosinophilic Esophagitis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Esophageal dysfunction, esophageal inflammation View